Everything You Need to Know About Treatment algorithm for HF for Step 1

Heart failure (HF) questions are some of the most “algorithmic” on Step 1/2: you’re expected to identify HFrEF vs HFpEF, decide if the patient is acutely decompensated vs stable, and then pick the next best drug (or what not to give). If you can run the treatment algorithm in your head, you’ll convert long stems into easy points.

---

Where this fits in First Aid (cross-references)

In First Aid for the USMLE Step 1, heart failure management concepts are primarily covered in:

• Cardiovascular Pharmacology:
  • Diuretics (loop, thiazide, K-sparing)
  • ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists
  • Vasodilators (hydralazine, nitrates)
  • Inotropes (dobutamine, milrinone)
• Cardiovascular Pathology/Physiology:
  • Systolic vs diastolic dysfunction, ventricular remodeling
  • Cardiomyopathies and causes of HF
• Renal (relevant for volume status + diuretic physiology)

Use FA as your “drug list,” but learn the flowchart here.

---

Definitions you must know (because treatment depends on them)

Heart failure

A clinical syndrome due to impaired cardiac output and/or elevated filling pressures causing:

• Dyspnea, orthopnea, PND
• Volume overload (edema, JVD, pulmonary crackles)
• Exercise intolerance, fatigue

HFrEF vs HFpEF (the fork in the road)

High-yield: Most of the “big mortality benefit” drugs are for HFrEF.

---

Pathophysiology (why these meds work)

HF triggers compensatory neurohormonal activation:

• SNS → ↑ HR/contractility initially, but chronic catecholamines cause arrhythmias, apoptosis, remodeling
• RAAS (renin → angiotensin II → aldosterone) → vasoconstriction + Na/H2O retention + fibrosis
• ADH → water retention → hyponatremia in severe HF
• Natriuretic peptides (BNP) rise to counteract RAAS but are often insufficient

Treatment is largely about:

1. Decongestion (diuretics)
2. Blocking maladaptive remodeling (ACEi/ARB/ARNI, beta-blockers, MRA, SGLT2)
3. Reducing afterload/preload (vasodilators)
4. Improving hemodynamics short-term in shock (inotropes/pressors)

---

Clinical presentation: what the vignette will hand you

Symptoms/signs

• Left-sided HF: dyspnea, orthopnea, PND, pulmonary edema
• Right-sided HF: JVD, hepatomegaly, ascites, peripheral edema (often secondary to left HF)

Classic exam clues

• S3: volume overload/dilated ventricle (HFrEF)
• S4: stiff ventricle (HFpEF)
• Bibasilar crackles, elevated JVP, cool extremities (low output)

---

Diagnosis: tests that matter for treatment decisions

Core workup (Step-style)

• BNP/NT-proBNP: elevated in HF (helps distinguish HF from COPD/asthma dyspnea)
• Echocardiogram: must-have to determine EF, wall motion, valve disease
• CXR: pulmonary edema, cardiomegaly, Kerley B lines
• ECG + troponins if ischemia suspected
• Labs before GDMT: creatinine/eGFR, potassium (ACEi/ARB/MRA considerations)

High-yield BNP pearl: BNP is released from ventricular myocardium in response to stretch. It promotes natriuresis and vasodilation, but clinically it’s a marker more than a treatment.

---

The big picture HF treatment algorithm (how Step wants you to think)

Step 1: Is this acute decompensated HF (ADHF) or chronic stable HF?

ADHF clues

• Rapid weight gain, pulmonary edema, severe dyspnea, hypoxia
• Hypertensive emergency, MI, arrhythmia trigger, medication nonadherence
• “Wet” (congested) vs “dry,” “warm” (perfused) vs “cold” (hypoperfused)

Chronic HF clues

• Stable symptoms over weeks, outpatient optimization, “on GDMT”

---

Acute decompensated HF (ADHF): what to do now

Initial stabilization

• Oxygen if hypoxemic
• Noninvasive ventilation (CPAP/BiPAP) for pulmonary edema (reduces preload/afterload)
• Treat triggers: MI, arrhythmia, infection, PE, nonadherence

“Wet” patient (pulmonary/peripheral congestion): diurese

• IV loop diuretic (furosemide, bumetanide, torsemide)
  • MOA (FA): inhibit Na-K-2Cl in thick ascending limb
  • AE: ototoxicity, hypokalemic metabolic alkalosis, dehydration

High-yield: In ADHF, use IV loops (gut edema can impair oral absorption).

Hypertensive pulmonary edema (high afterload): add vasodilators

• IV nitrates (venodilation → ↓ preload)
• Sometimes nitroprusside (balanced vasodilation) in monitored settings

“Cold and wet” (hypoperfusion + congestion): think cardiogenic shock physiology

• If hypotensive/poor perfusion: consider inotropes
  • Dobutamine (β1 agonist) → ↑ inotropy, some vasodilation
  • Milrinone (PDE-3 inhibitor) → ↑ cAMP in myocardium + vasodilation
    • AE: arrhythmias, hypotension
• If profound hypotension: pressors (Step 2/ICU logic), plus treat cause.

Do NOT start/titrate chronic mortality meds in unstable shocky patients. Stabilize first.

ADHF “don’ts” (common Step traps)

• Non-DHP CCBs (verapamil/diltiazem) can worsen HFrEF (negative inotropy)
• NSAIDs worsen HF (Na/H2O retention; blunts diuretics)
• Thiazolidinediones (pioglitazone) cause fluid retention
• Be careful with excess IV fluids unless there’s a clear indication

---

Chronic HFrEF (systolic HF): GDMT you should reflexively know

For Step purposes, think in two layers:

Layer 1: Symptom relief (doesn’t necessarily improve survival)

• Loop diuretics for volume overload (edema, pulmonary congestion)

Layer 2: Mortality benefit (the Step “core four” concept)

Foundational HFrEF therapy (mortality-reducing):

1. ARNI (preferred) or ACE inhibitor/ARB
2. Evidence-based beta-blocker
3. Mineralocorticoid receptor antagonist (MRA)
4. SGLT2 inhibitor

Even if your Step 1 resources don’t emphasize SGLT2 as much, Step 2-style questions increasingly do.

---

1) RAAS pathway inhibition: ACEi/ARB/ARNI

ACE inhibitors (enalapril, lisinopril)

• ↓ Ang II → ↓ afterload/preload, ↓ remodeling
• AE (FA classic):
  • Cough, angioedema (↑ bradykinin)
  • Hyperkalemia
  • Increased creatinine (especially with bilateral renal artery stenosis)
  • Teratogenic

ARBs (losartan, valsartan)

• Similar benefits, no cough, less angioedema

ARNI: sacubitril/valsartan

• Sacubitril inhibits neprilysin → ↑ natriuretic peptides (↑ vasodilation/natriuresis)
• Combined with ARB to block RAAS compensation
• Step pearl: Risk of angioedema, and you need a washout when switching from ACEi due to bradykinin-related risk.

---

2) Beta-blockers (only the evidence-based ones)

Use in stable HFrEF (not in acute cardiogenic shock).

• Metoprolol succinate, carvedilol, bisoprolol
• Benefits: ↓ sympathetic toxicity, ↓ arrhythmias, improved remodeling

High-yield trap: Beta-blockers can transiently worsen symptoms when started; you start low and go slow in stable patients.

---

3) Mineralocorticoid receptor antagonists (MRAs)

• Spironolactone, eplerenone
• Block aldosterone → ↓ Na retention and ↓ fibrosis/remodeling
• AE (FA):
  • Hyperkalemia
  • Spironolactone: gynecomastia, impotence (antiandrogen effects)
  • Eplerenone: fewer endocrine effects

---

4) SGLT2 inhibitors (dapagliflozin, empagliflozin)

• Benefits in HFrEF with or without diabetes (Step 2 trend)
• AE to recognize:
  • Genital mycotic infections
  • Euglycemic ketoacidosis (rare)
  • Volume depletion

---

Add-on therapies and special situations (high yield)

Hydralazine + nitrates

• Particularly beneficial in:
  • Patients who cannot tolerate ACEi/ARB/ARNI (e.g., renal failure, hyperkalemia)
  • Often tested as beneficial in Black patients with HFrEF as add-on therapy
• Hydralazine: ↓ afterload (arteriolar dilation)
• Nitrates: ↓ preload (venodilation)

Digoxin

• Increases inotropy by inhibiting Na⁺/K⁺ ATPase → ↑ intracellular Ca²⁺
• Role: symptom control, reduces hospitalizations (not a big mortality drug)
• Toxicity (FA classics): nausea, arrhythmias, yellow vision
• Toxicity worsened by hypokalemia (e.g., from loop diuretics)

Ivabradine (Step 2-level)

• Lowers HR by inhibiting funny current ($I_f$) in SA node
• Consider if sinus rhythm, HR still elevated despite beta-blocker (nuanced; less Step 1)

Anticoagulation

• Not routine for HF alone; indicated for AF, LV thrombus, etc.

---

Chronic HFpEF (diastolic HF): what Step expects

HFpEF is about stiff ventricle and high filling pressures.

Goals

• Control blood pressure aggressively
• Diurese for congestion (careful not to underfill)
• Treat contributors:
  • Ischemia
  • AF (rate/rhythm control)
  • Obesity, OSA
  • Valvular disease

High-yield: There’s no single “mortality miracle” regimen in HFpEF like HFrEF. On exams, the correct move is often diuretics + manage HTN/comorbidities.

---

Cardiomyopathies: quick associations that feed into HF questions

Dilated cardiomyopathy (DCM) → HFrEF

• Causes (remember: ABCDE-style thinking):
  • Alcohol (and toxins like doxorubicin)
  • Beriberi (thiamine deficiency)
  • Coxsackie B myocarditis
  • Doxorubicin/daunorubicin
  • End-stage Chagas (also consider peripartum CM)
• Treatment: HFrEF GDMT + manage cause (e.g., stop alcohol)

Hypertrophic cardiomyopathy (HCM)

• Diastolic dysfunction, systolic anterior motion of mitral valve
• Treatment: beta-blockers, non-DHP CCBs; avoid dehydration/excess preload reduction

Restrictive cardiomyopathy

• Amyloidosis, sarcoidosis, hemochromatosis, radiation
• Often looks like right-sided failure with preserved EF early
• Treatment: treat underlying disease + cautious diuresis

---

Putting it all together: Step-style decision table

---

High-yield “one-liners” you can recall under pressure

• HFrEF: treat remodeling—ACEi/ARB/ARNI + beta-blocker + MRA (+ SGLT2); use loop diuretics for congestion.
• HFpEF: think stiff ventricle—diuretics + BP control + treat comorbidities.
• ADHF: stabilize breathing, then IV loop diuretics; add vasodilators if hypertensive; inotropes if shock.
• BNP high supports HF; echo decides HFrEF vs HFpEF.
• Avoid NSAIDs and negative inotropes (notably verapamil/diltiazem) in HFrEF.

---

Quick self-check (mini practice)

1. A man with prior MI has EF 30% and chronic dyspnea. Which medication improves survival?
   → ACE inhibitor (also beta-blocker, MRA; concept = GDMT)

2. A woman with acute pulmonary edema and severe hypertension: immediate therapy?
   → IV loop diuretic + nitrates (after oxygen/ventilation as needed)

3. An older patient with long-standing HTN, EF 60%, S4, pulmonary congestion: outpatient focus?
   → BP control + diuretics, treat AF/ischemia if present (HFpEF strategy)